Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Latest News on ALLR

Mar 25, 2025, 9:09 AM EDT - 8 days ago

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Mar 14, 2025, 4:30 AM EDT - 19 days ago

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Mar 13, 2025, 8:30 AM EDT - 20 days ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 6, 2025, 8:00 AM EST - 27 days ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Feb 24, 2025, 8:00 AM EST - 5 weeks ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 14, 2025, 10:00 AM EST - 6 weeks ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 13, 2025, 10:00 AM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Shareholders to Inquire about Securities Investigation

Feb 12, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect

Feb 11, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out

Feb 10, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation

Feb 9, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation

Feb 7, 2025, 10:00 AM EST - 7 weeks ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 6, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect

Feb 6, 2025, 8:00 AM EST - 7 weeks ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 4, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation

Feb 3, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out

Feb 2, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out

Jan 31, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect

Jan 30, 2025, 8:00 AM EST - 2 months ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Jan 8, 2025, 10:00 AM EST - 3 months ago

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation

Nov 18, 2024, 8:00 AM EST - 4 months ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 11, 2024, 3:45 PM EST - 5 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 11, 2024, 11:15 AM EST - 5 months ago

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Nov 9, 2024, 12:30 PM EST - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Nov 8, 2024, 7:00 PM EST - 5 months ago

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 8, 2024, 9:45 AM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Nov 7, 2024, 11:00 AM EST - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Nov 6, 2024, 11:00 AM EST - 5 months ago

The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud

Nov 4, 2024, 11:00 AM EST - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud

Oct 27, 2024, 11:00 AM EDT - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 22, 2024, 8:00 AM EDT - 5 months ago

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

Oct 17, 2024, 11:00 AM EDT - 5 months ago

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm

Oct 10, 2024, 8:00 AM EDT - 6 months ago

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Oct 3, 2024, 8:00 AM EDT - 6 months ago

Market Cap	4.15M
Revenue (ttm)	0.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.10

Volume	1,386,300
Avg Vol	2,637,090
Day's Range	N/A - N/A
Shares Out	4.43M
Stochastic %K	8%
Beta	0.26
Analysts	Hold
Price Target	$6,993.00